Can a cancer drug stop mouth cancer before it starts?
NCT ID NCT02882282
Summary
This study tested whether the immunotherapy drug pembrolizumab could prevent oral cancer in people with high-risk precancerous mouth lesions. Fifteen participants were randomly assigned to either receive the drug or be observed without treatment. The main goal was to see if the drug helped patients stay cancer-free longer compared to just watching and waiting.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ORAL CAVITY CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.